Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 39
2009 55
2010 56
2011 51
2012 51
2013 56
2014 66
2015 72
2016 84
2017 92
2018 128
2019 153
2020 115
2021 112
2022 113
2023 124
2024 158
2025 88

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,370 results

Results by year

Filters applied: . Clear all
Page 1
FIGO staging of endometrial cancer: 2023.
Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N; Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee. Berek JS, et al. J Gynecol Oncol. 2023 Sep;34(5):e85. doi: 10.3802/jgo.2023.34.e85. Epub 2023 Aug 8. J Gynecol Oncol. 2023. PMID: 37593813 Free PMC article.
Cisplatin versus carboplatin?
Karacin P. Karacin P. J Gynecol Oncol. 2025 Mar;36(2):e88. doi: 10.3802/jgo.2025.36.e88. Epub 2025 Mar 10. J Gynecol Oncol. 2025. PMID: 40114557 Free PMC article. No abstract available.
Time for enhancing government-led primary prevention of cervical cancer.
Min KJ, Suh DH, Baba T, Chen X, Kim JW, Kobayashi Y, Kwon J, Lim MC, Lee JY, Nagase S, Park JY, Tangjitgamol S, Watari H. Min KJ, et al. J Gynecol Oncol. 2021 Jan;32(1):e12. doi: 10.3802/jgo.2021.32.e12. Epub 2020 Dec 11. J Gynecol Oncol. 2021. PMID: 33327045 Free PMC article. No abstract available.
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D. Okazawa-Sakai M, et al. J Gynecol Oncol. 2024 Oct 21. doi: 10.3802/jgo.2025.36.e38. Online ahead of print. J Gynecol Oncol. 2024. PMID: 39453391 Free article.
1,370 results